Background
==========

Malaria remains a major cause of death and illness in children and adults in tropical settings. An integrated strategy is recommended which ensures access to treatment with effective anti-malarials, while also undertaking preventative measures that target vector control \[[@B1]\]. ACT became the recommended treatment for uncomplicated malaria, as resistance emerged to conventional monotherapies, including sulphadoxine-pyrimethamine (SP), chloroquine and amodiaquine, thereby reducing their therapeutic efficacy. Over the last decade, countries have revised their national malaria treatment policies to adopt ACT as the first-line recommended treatment for uncomplicated malaria. Although these policies are now well established, there are persistent problems with their implementation.

Evidence from several settings on malaria case management report problems with the choice of treatment, showing that ACT is often underused and many patients continue to receive less effective anti-malarials, such as SP \[[@B2]-[@B4]\]. There are also concerns about the availability and use of artemisinin monotherapy, as drug resistance is more likely to develop if artemisinin derivatives are taken without a partner drug \[[@B5],[@B6]\]. Problems with the dispensing of malaria treatment have also been observed, with patients frequently receiving inadequate doses and without advice on how the medicines should be taken \[[@B2],[@B7]\]. Ensuring accuracy of drug dispensing is particularly challenging for pharmacies and other drug retailers which typically stock a multitude of different types of ACT and the accurate dosage depends not only on the patient\'s age or weight but varies by brand depending on the formulation and composition of the active ingredients \[[@B8],[@B9]\].

In Nigeria, it is estimated that children under five years of age have between two and four episodes of malaria each year, and ensuring prompt access to effective treatment is a key strategy of the Nigerian Federal Ministry of Health \[[@B10]\]. At the level of primary care, the national malaria treatment guidelines state that diagnosis should be based on symptoms using the Integrated Management of Childhood Illnesses (IMCI) classification \[[@B10]\]. Thus, patients presenting with febrile illness at health facilities without diagnostic testing available should be presumptively treated for malaria. ACT became the recommended treatment for uncomplicated malaria in 2005 and at this time new treatment guidelines and training materials were developed \[[@B10]-[@B12]\]. The first-line recommended treatment is artemether-lumefantrine (AL), though treatment with artesunate-amodiaquine (ASAQ), artesunate-mefloquine (ASMQ) and dihydroartemisinin-piperaquine (DHAPQ) are also considered acceptable \[[@B12]\]. The policy is also clear that SP is reserved for intermittent preventive treatment in pregnancy, and cases of severe malaria should be treated using quinine injection, artemether injection, or artesunate (either as an injection or suppository); otherwise the use of monotherapies is no longer recommended.

The provision and utilization of malaria treatment in south-eastern Nigeria is well researched, with evidence from household surveys, patient records and from health care providers at a range of health facilities showing that many febrile patients do not receive the recommended anti-malarial \[[@B4],[@B13]-[@B16]\]. Much less is known about the quality of care provided at health facilities, and this study explores these concerns directly by collecting data from patients exiting public health facilities and medicine retailers. These types of facilities are the main providers of malaria treatment at the primary care level \[[@B14]\]. This paper describes the characteristics of patients and the health facilities they attend, and their experience of care, including the nature of the consultation, the provision of anti-malarial treatments and the quality of drug dispensing. The paper also investigates whether patient, health worker or facility factors are associated with receiving ACT.

Methods
=======

Study area
----------

The study was undertaken in two study sites in Enugu State in south-eastern Nigeria: Enugu urban (comprising of Enugu East, Enugu South and Enugu North local government areas (LGAs)) and Udi LGA. Enugu urban is the largest predominantly urban area in Enugu State, and Udi LGA is rural. Malaria is endemic in Enugu State, and occurs all year round. The people of Enugu are of Igbo ethnicity and speak the Igbo language. The activities of the majority of the population include farming, fishing, wine tapping, and poultry keeping and rearing of domestic animals; the main agriculture season runs from November to February.

ACT was introduced into the study site in 2005 by the State Malaria Control Programme. The implementation package consisted of training health workers on symptomatic diagnosis, change in antimalarial policy and rational prescription of antimalarials and was accompanied by a community awareness campaign.

Study setting
-------------

The study was undertaken at public primary health facilities, private sector pharmacies and patent medicine dealers (PMDs) in Enugu State, south-eastern Nigeria \[[@B17]\]. The term PMD refers to retail outlets that are licensed to sell over the counter pharmaceutical products, though often hold a wider range of stock, and typically have no formal training \[[@B18]\]. Pharmacies and PMDs are a major source of malaria treatment \[[@B14],[@B19]\]. These facilities are medicine retailers and do not routinely offer clinical care or diagnostic services. At the primary care level, presumptive treatment of malaria is recommended in febrile patients, as few public facilities offer malaria microscopy or RDTs. Primary health centres are usually staffed by community health officers and community health extension workers and supported by registered nurses and midwives \[[@B20]\].

Study design
------------

A stratified multistage cluster survey was conducted between July and December 2009. The survey sampling was clustered in 16 randomly selected communities and stratified by type of facility: i) public facilities including primary health centres, dispensaries and health posts, and ii) pharmacies and PMDs. Within each community all public primary health centres were included due to their small number. There are a large number of pharmacies and PMDs, and these were randomly selected with probability proportionate to size assuming that a total of 80 (out of 298) medicine retailers could be visited given the financial resources and time available. All health workers within each facility responsible for prescribing or dispensing medicines were included in the study.

A survey sample of 20 patients per public facility was calculated to estimate the primary outcome, the proportion of febrile patients receiving the recommended treatment for malaria, with a precision of +/- 13%, assuming that the variability (intra-cluster correlation, ICC) in treatment between facilities is 0.3 \[[@B21]\]. For pharmacies and PMDs, 14 patients per facility allows the primary outcome to be calculated with a precision of +/- 6.6% assuming the same degree of variation. The estimates assume a prevalence of 50% for the primary outcome and give the maximum range for precision (if the observed prevalence by higher or lower than 50% then greater precision would be achieved). The sampling was based on an enumeration of health facilities and their staff conducted in April 2009.

Survey activities
-----------------

In advance of the survey a field team visited each facility to explain the purpose of the survey to the head of the facility and obtain informed written consent. Informed consent was reconfirmed verbally on the day of the actual survey. The survey questionnaires were developed specifically for the study and pretested on a non-random sample of individuals with characteristics similar to those of the survey population but not chosen for inclusion in the survey. Survey teams were trained on procedures for conducting the survey and involved in the pretesting and revision of the questionnaires. Site supervisors monitored and supervised all aspects of data collection.

Data were collected using three structured approaches; a patient exit questionnaire, a health worker survey and a health facility audit. Written consent from patients and caregivers (who may or may not be accompanied by the patient) exiting the health facility was sought before screening to determine their eligibility to participate in the survey. An individual was considered eligible if s/he reported seeking treatment for a fever or if s/he had received an ACT. Treatment may be sought for themselves, a child or another person who is not present (the latter applies only at medicine retailers). Individuals that were exiting a health facility were assessed in turn until the patient quota was reached. All workers that were involved in prescribing or dispensing malaria treatment and were available at the time of the survey were invited to complete the health worker survey and written consent was obtained from all participants.

The patient exit questionnaire collected data on the patient\'s prior treatment seeking and use of anti-malarials, reasons for attendance, the consultation and diagnosis, prescriptions and medicines received, the cost of treatment seeking and the demographic characteristics of the patient. The health worker questionnaire captured data on their characteristics, access to in-service training and national malaria treatment guidelines, malaria knowledge and treatment practices. The health worker survey was conducted once all the patient exit questionnaires had been completed to ensure that the treatment received by patients was not influenced by the content of the health worker questionnaire and the patient exit data best reflects current prescribing practices. The health facility audit was conducted following the health worker survey and collected data on the characteristics of the health facility, diagnostic services, management and procurement of medicine, including the availability of ACT.

Definitions
-----------

The treatment received by patients was assessed against the national malaria treatment guidelines, which recommends that patients with a fever are presumptively treated with an ACT, with the exception of pregnant women in the first trimester. The accuracy of the ACT dose provided to patients was assessed in accordance with dosage recommendations based on the patient\'s age and the type and composition of ACT received. Thus, the analysis takes into account that the correct number of tablets (or powder sachets) varies by brand, the amount of active ingredients contained in each tablet and whether they are co-formulated or co-blistered. Suspensions were excluded from the analysis on dosing. As patient age was used as a proxy for weight \[[@B11],[@B22]\] this may cause some error in estimating the accuracy of dosing among children, though this would not apply to adults. Patient knowledge on the dose regimen was ascertained by asking the patient or their caregiver to explain how and when the medicine should be taken. Knowledge was considered accurate if they reported the number of tablets (or powder sachets) which should be taken per day over 3 days that corresponds to the specific brand of ACT received, and the patient\'s age. Suspensions were excluded from the analysis due to the difficulties in accessing the accuracy of the correct dose.

Statistical analysis
--------------------

Data were entered and verified using Microsoft Access 2007 (Microsoft Inc., Redmond, Washington) and analysed using STATA version 11.0 (STATA Corporation, College Station, Texas) that allows for complex survey design by identifying different probabilities of selection (sampling weights), clustering and stratification (applying the prefix svy) \[[@B23]\]. Thus, all percentages and odds ratios reported are population-average estimates which have been adjusted to take into account the stratification, clustering and sampling weights of the study design. The weights are equal to the inverse probability of being sampled and took into account the sampling probabilities at the facility, health worker and patient level. At the patient level, number of days it took to recruit patients was used to create a proxy for the volume of patients, with the less time indicative of a larger facility.

Treatment outcomes by strata were compared using the Rao and Scott chi-square correction \[[@B24]\]. Survey logistic regression was used to assess factors associated with receiving the recommended treatment. The following were investigated for their potential association: characteristics of the patient and health worker, patient consultation, and the resources available at the health facility (all factors are listed in Table six). Factors associated with receiving the recommended treatment were investigated in the multivariable model if the univariable association was statistically significant at the 10 percent level, or the odds ratio was less than 0.5 or greater than 1.5. Factors were retained in this multivariable model if they remained significantly associated at the 10% level of significance or with an adjusted odds ratio less than 0.5 or greater than 1.5. Models were compared using an adjusted Wald test. Pregnant women and children under the age of 6 months were excluded from the analysis because the national malaria treatment guidelines have alternative recommendations for these groups.

Ethical approval
----------------

Ethical approval for this study was obtained from the ethics committees of University of Nigeria and London School of Hygiene and Tropical Medicine.

Results
=======

Patient characteristics
-----------------------

Data were collected from 100 health facilities and the analysis is based on exit data collected from 1,642 febrile patients attending public facilities and medicine retailers and 149 health workers (Figure [1](#F1){ref-type="fig"}). There was notable variation in the characteristics of patients attending the different types of health facility (Table [1](#T1){ref-type="table"}). More than half (57%) of the patients treated at public health facilities were children, while 80% of the cases presenting at pharmacies and PMDs were adults. Treatment-seeking also varied by education levels and socioeconomic status (SES), with respondents surveyed at medicine retailers more likely to have tertiary education and be of a higher wealth quintile. At medicine retailers81% of patients reported it was the first time that they had sought treatment for this illness episode, and 43% had sought treatment on the same or day following the onset of symptoms. While at public facilities 61% of patients at public facilities were seeking treatment for the first time and the time before treatment was much longer, with only 16% seeking treatment on the same or day following the onset of symptoms. When asked about their choice of health facility, many respondents said that they had sought treatment at this facility for past illnesses (54%) and it was convenient (55%). In addition, patients at public health facilities often mentioned the lower cost of treatment, while the reputation of the provider and the availability of drugs were more often cited at medicine retailers.

![**Study population**.](1475-2875-10-155-1){#F1}

###### 

Patient Characteristics by type of facility\*

                                                        Public   Medicine retailer   Total                        
  ----------------------------------------------------- -------- ------------------- ------- ------ ------ ------ ---------
  **Patient gender^i^**                                                                                           
                                                                                                                  
   Male                                                 218      45.4                624     56.4   842    55.5   0.006
                                                                                                                  
   Female                                               242      54.6                536     43.6   778    44.5   
                                                                                                                  
  **Patient age**                                                                                                 
                                                                                                                  
   \>15 years (adult)                                   185      42.8                913     79.6   1098   76.7   \<0.001
                                                                                                                  
   10-15 years                                          27       6.6                 85      7.3    112    7.3    
                                                                                                                  
   5-9 years                                            61       12.6                71      4.6    132    5.3    
                                                                                                                  
   \<5 years                                            193      38.0                107     8.4    300    10.7   
                                                                                                                  
  **Patient socioeconomic status^ii^**                                                                            
                                                                                                                  
   Poorest quintile                                     223      46.4                343     15.7   566    18.1   \<0.001
                                                                                                                  
   Second quintile                                      97       20.4                219     20.0   316    20.1   
                                                                                                                  
   Third quintile                                       55       11.8                219     21.3   274    20.6   
                                                                                                                  
   Fourth quintile                                      56       13.5                189     21.2   245    20.6   
                                                                                                                  
   Richest quintile                                     35       8.0                 206     21.8   241    20.7   
                                                                                                                  
  **Education level of patient (or caregiver)^iii^**                                                              
                                                                                                                  
   No formal education                                  25       5.8                 41      1.3    66     1.6    \<0.001
                                                                                                                  
   Primary education                                    116      28.0                198     12.5   314    13.7   
                                                                                                                  
   Secondary education                                  213      46.1                469     39.7   682    40.2   
                                                                                                                  
   Tertiary education                                   93       20.0                445     46.6   538    44.5   
                                                                                                                  
  **Was first time sought treatment^iv^**                                                                         
                                                                                                                  
   Yes                                                  269      61.4                896     81.7   1165   81.1   \<0.001
                                                                                                                  
   No                                                   196      38.7                273     18.3   469    19.9   
                                                                                                                  
  **Number of days since start of symptoms^v^**                                                                   
                                                                                                                  
   None (same day)                                      14       3.3                 234     22.1   248    20.6   \<0.001
                                                                                                                  
   1 day                                                71       12.6                259     21.2   330    20.5   
                                                                                                                  
   2 days                                               93       19.3                228     21.2   321    21.1   
                                                                                                                  
   3-5 days                                             202      45.4                284     23.5   486    25.3   
                                                                                                                  
   6+ days                                              85       19.4                169     12.0   254    12.6   
                                                                                                                  
  **Reasons given for choice of health facility^vi^**                                                             
                                                                                                                  
   Convenient                                           229      49.2                617     55.9   846    55.4   0.284
                                                                                                                  
   Used previously                                      243      48.6                732     54.7   975    54.2   0.346
                                                                                                                  
   Good reputation                                      145      30.1                529     49.6   674    48.1   0.002
                                                                                                                  
   Availability of drugs                                127      23.3                548     48.7   675    46.7   0.001
                                                                                                                  
   Inexpensive                                          206      46.2                178     13.3   384    15.9   \<0.001
                                                                                                                  
   Qualification of staff                               132      24.7                174     12.9   306    13.9   0.011

i missing 22 responses: 6 from public and 16 from medicine retailer

ii Principal components analysis was undertaken to generate a SES index based on household asset ownership \[[@B33]\]. The SES index was disaggregated into wealth quintiles.

iii missing 42 responses: 19 from public and 23 from medicine retailer

iv missing 8 responses: 1 from public and 7 from medicine retailer

v missing 3 responses: 1 from public and 2 from medicine retailer

vi more than one reason could be given

Health facility and health worker characteristics
-------------------------------------------------

The provision of basic equipment, such as weighing scales and thermometers was good in public health facilities, though more mixed in pharmacies and PMDs (Table [2](#T2){ref-type="table"}). Very few health facilities offered malaria microscopy testing and none of the health facilities surveyed used RDTs. At the time of the survey, all health facilities reported that they had anti-malarials in stock, and field staff verified that ACT was in stock in 80% of health facilities. There was some variation by facility type, with 71% of public health centres and 89% of pharmacies and PMDs stocking at least one ACT. Two-thirds of health facilities had artemether-lumefantrine (AL) available, though other types of ACT were common in medicine retailers. Artemisinin monotherapy was available in 96% of medicine retailers while the vast majority (90%) of facilities also had SP as well as other types of anti-malarials available; these included less effective conventional treatments such as chloroquine and amodiaquine.

###### 

Facility Characteristics

                                                                                        Public       Medicine retailer   Total                                          
  ------------------------------------------------------------------------------------- ------------ ------------------- ---------------- ------- ------------- ------- -------------
  **HEALTH FACILITIES**                                                                 **N = 20**   **%**               **N = 80**       **%**   **N = 100**   **%**   **P value**
                                                                                                                                                                        
  **Equipment and services available**                                                                                                                                  
                                                                                                                                                                        
   Weighing scale†                                                                      19           94.1                36               50.0    55            53.1    \<0.001
                                                                                                                                                                        
   Thermometer                                                                          19           94.2                35               46.5    54            49.8    \<0.001
                                                                                                                                                                        
   Microscopy services†                                                                 3            12.8                0                \-      3             0.9     \<0.001
                                                                                                                                                                        
   RDT                                                                                  0            \-                  0                \-      0             \-      \-
                                                                                                                                                                        
  **Availability of anti-malarials**                                                                                                                                    
                                                                                                                                                                        
   Any anti-malarial                                                                    20           100.0               80               100.0   100           100.0   \-
                                                                                                                                                                        
   Artesunate monotherapy                                                               5            24.6                76               96.1    81            91.1    \<0.001
                                                                                                                                                                        
   Sulphadoxine Pyrimethamine (SP) †                                                    18           89.8                71               89.9    89            89.9    0.982
                                                                                                                                                                        
   Chloroquine                                                                          14           71.1                77               96.8    91            95.0    \<0.001
                                                                                                                                                                        
   Quinine                                                                              4            20.3                70               89.1    74            84.3    \<0.001
                                                                                                                                                                        
   Amodiaquine                                                                          3            14.4                60               85.3    63            80.3    \<0.001
                                                                                                                                                                        
   Any type of ACT                                                                      14           71.1                66               89.6    80            88.3    \<0.001
                                                                                                                                                                        
   Artemether Lumefantrine (AL)                                                         12           65.6                64               79.6    66            78.4    \<0.001
                                                                                                                                                                        
   Artesunate Amodiaquine (ASAQ)                                                        2            8.6                 57               78.8    59            73.9    \<0.001
                                                                                                                                                                        
   Artesunate Mefloquine (ASMQ)                                                         0            \-                  35               52.9    35            49.2    \<0.001
                                                                                                                                                                        
   Artesunate Sulphadoxine-Pyrimethamine (ASSP)                                         0            \-                  18               28.4    18            26.4    \<0.001
                                                                                                                                                                        
   Dihydroartemisinin-Piperaquine (DHAPQ)                                               0            \-                  55               78.0    55            72.6    \<0.001
                                                                                                                                                                        
  **Median cost of ACT**(& IQ range)                                                                                                                                    
                                                                                                                                                                        
   Adult dose of any ACT                                                                \-           600 (350, 750)      600 (350, 750)   \-                            
                                                                                                                                                                        
   Child dose of any ACT                                                                \-           350 (260, 600)      350 (250, 600)   \-                            
                                                                                                                                                                        
   Adult dose of AL                                                                     \-           750 (650, 835)      750 (650, 820)   \-                            
                                                                                                                                                                        
   Child dose of AL                                                                     \-           650 (580, 750)      650 (520, 700)   \-                            
                                                                                                                                                                        
  **HEALTH WORKERS**                                                                    N = 50       \%                  N = 99           \%      N = 149       \%      P value
                                                                                                                                                                        
   Doctor                                                                               7            14.0                0                        9             1.7     \<0.001
                                                                                                                                                                        
   Nurse or Midwife                                                                     7            14.0                7                7.3     14            8.1     
                                                                                                                                                                        
   Community Health Officer                                                             14           28.0                1                1.3     15            4.5     
                                                                                                                                                                        
   Community Health Extension Worker                                                    22           44.0                3                4.1     25            8.9     
                                                                                                                                                                        
   Pharmacist‡                                                                          \-                               3                3.9     3             3.4     
                                                                                                                                                                        
   PMD or pharmacy attendant‡                                                           \-                               85               83.4    85            73.5    
                                                                                                                                                                        
  HW has attended malaria training in past 3 years                                      13           24.6                31               33.0    44            31.9    0.011
                                                                                                                                                                        
  HW has access to malaria treatment guidelines                                         15           30.9                4                5.2     19            8.5     \<0.001
                                                                                                                                                                        
  HW accurately reported ACTs are the recommended treatment for uncomplicated malaria   38           77.2                44               62.2    82            65.4    \<0.001

† missing response from one pharmacy

‡ not applicable in public facilities

All the public facilities reported that ACT was available to patients free of charge. In pharmacies and PMDs the median price of an ACT was 600 Naira for an adult dose and 350 Naira for a child dose (which is approximately equivalent to USD \$4.00 and USD \$2.30). The median price of AL was higher at 750 Naira for an adult dose and 650 Naira for a child dose (equivalent to USD \$6.00 and USD \$4.30).

Just under half (44%) of workers in public facilities were community health extension workers, semi-skilled health workers trained in primary care, and while junior to the other cadres listed in Table [2](#T2){ref-type="table"} may prescribe treatment or undertake minor procedures \[[@B20]\]. In the medicine retailers the majority (83%) described themselves as patent medicine dealers or pharmacy attendants.

Knowledge of malaria treatment was variable, though better in public facilities, as 80% of workers in public facilities reported that ACT is the recommended treatment for uncomplicated malaria, compared to 62% of workers in pharmacies and PMDs. Moreover, less than one in three health workers surveyed had attended an in-service malaria training workshop over the past three years and relatively few (9%) had access to the malaria treatment guidelines (31% of public health workers and 5% of health workers at pharmacies and PMDs).

Patient consultation, prescription and requests for medicine
------------------------------------------------------------

The nature of the patient\'s consultation differed by type of health facility (Table [3](#T3){ref-type="table"}). In public health facilities 95% of respondents reported the health workers were told of the patient\'s symptoms, and 90% reported that they had told the health worker about the patient\'s fever. Patients reported to have been physically examined in 65% of cases, 50% had their temperature taken, though just 6% of patients were tested for malaria. At public facilities with microscopy testing available 21% of patients were tested for malaria. In pharmacies and PMDs patients were rarely examined (6%) or tested (\<1%), though in 32% of cases health workers were told about the patient\'s symptoms and asked further questions.

###### 

Patient consultation

                                                              Public             Medicine retailer   Total              
  ----------------------------------------------------------- ------------------ ------------------- ------------------ ---------
  **Patient reported consultation**                                                                                     
                                                                                                                        
  Told HW about patient symptoms                              94.9 (94.4-95.4)   44.3 (36.9-52.0)    48.3 (41.3-55.4)   \<0.001
                                                                                                                        
  Told HW that had a fever                                    89.8 (87.2-91.9)   40.3 (33.0-48.2)    44.3 (37.1-51.4)   \<0.001
                                                                                                                        
  HW asked follow up questions about patient\'s symptoms      79.9 (76.3-83.0)   32.0 (25.0-39.9)    35.7 (29.1-43.1)   \<0.001
                                                                                                                        
  Patient was physically examined                             65.1 (48.8-78.5)   6.2 (3.5-10.5)      10.8 (7.8-14.5)    \<0.001
                                                                                                                        
  Patient had temperature taken                               49.7 (38.6-60.9)   1.7 (0.6-4.9)       5.5 (3.9-7.8)      \<0.001
                                                                                                                        
  Patient tested for malaria at this facility                 5.8 (3.6-9.3)      0.2 (0.0-1.4)       0.7 (0.3-1.3)      \<0.001
                                                                                                                        
  **Patient requests for medicine**                                                                                     
                                                                                                                        
  \% of patients that asked for:                                                                                        
                                                                                                                        
   any type of medicine                                       2.8 (1.9-4.2)      65.4 (57.9-72.3)    60.5 (53.7-66.9)   \<0.001
                                                                                                                        
   an anti-malarial                                           1.2 (0.7-2.1)      58.3 (51.1-65.2)    53.8 (47.3-60.2)   \<0.001
                                                                                                                        
   any ACT                                                    0.9 (0.4-1.9)      16.0 (11.1-22.5)    14.8 (10.3-20.9)   \<0.001
                                                                                                                        
   Artemisinin monotherapy                                    0                  11.5 (8.6-15.3)     10.6 (8.0-14.1)    0.162
                                                                                                                        
   Amodiaquine                                                0                  1.6 (0.8-3.4)       1.5 (0.7-3.2)      0.402
                                                                                                                        
   Chloroquine                                                0.1 (0.0-0.4)      1.3 (0.6-2.7)       1.2 (0.6-2.5)      \<0.001
                                                                                                                        
   Quinine                                                    0                  0.7 (0.2-2.6)       0.7 (0.2-2.4)      0.631
                                                                                                                        
   SP                                                         0.1 (0.1-0.1)      26.2 (21.5-31.5)    24.1 (19.8-29.1)   \<0.001
                                                                                                                        
  **Anti-malarial prescriptions**                                                                                       
                                                                                                                        
  \% patients prescription (from any facility)                94.2 (92.4-95.6)   15.4 (10.7-21.5)    21.6 (17.1-26.9)   \<0.001
                                                                                                                        
  \% patients that received prescription from this facility   94.2 (92.4-95.6)   1.8 (0.7-4.0)       8.8 (7.3-11.0)     \<0.001
                                                                                                                        
  \% patients that were prescribed\*:                                            \-                  \-                 \-
                                                                                                                        
   an anti-malarial^†^                                        78.4 (72.6-83.3)   \-                  \-                 \-
                                                                                                                        
   any ACT^‡^                                                 34.0 (21.9-48.7)   \-                  \-                 \-
                                                                                                                        
   Artemisinin monotherapy                                    4.7 (3.1-7.1)      \-                  \-                 \-
                                                                                                                        
   Amodiaquine                                                1.1 (0.9-1.5)      \-                  \-                 \-
                                                                                                                        
   Chloroquine                                                3.3 (0.8-11.6)     \-                  \-                 \-
                                                                                                                        
   Quinine                                                    0.2 (0.0-3.1)      \-                  \-                 \-
                                                                                                                        
   SP                                                         34.7 (21.7-50.6)   \-                  \-                 \-

\* Reported only for public health facilities

† At public facilities 73.4% of children under five years were prescribed an antimalarial.

‡ At public facilities 51.5% of children under five years were prescribed an ACT. At public health facilities with ACTs in stock 43.8% of patients (all ages) and 57.9% of children under five years were prescribed an ACT.

The majority of patients attending public facilities had medicines prescribed and in 78% of cases the prescription was for an anti-malarial. ACT was prescribed to 34% of patients seeking treatment, though as many patients were prescribed SP, which is no longer recommended for treating malaria.

At pharmacies and PMDs, 15% of patients had a prescription and patients often asked for a specific medicine. At these facilities, 58% of patients attending asked for an anti-malarial. Patients often asked for SP (26%), though also requested ACT (16%) and artemisinin-monotherapy (12%). Almost all (96%) of those patients that asked for an anti-malarial also received the medicine they had requested.

Malaria treatment received by patients
--------------------------------------

Overall, the majority of patients received an anti-malarial, though ACT was received by only 22% of all patients attending health facilities and by 29% of children under five years of age (Table [4](#T4){ref-type="table"}). SP is no longer recommended, though still frequently used, and 38% of patients had received this medicine. At public facilities, differences were observed between the proportion of patients that were prescribed and received antimalarials at facilities which had ACT in stock. The proportion of patients that received an antimalarial at public facilities was also low compared to the medicine retailers. There were, however, few differences between the proportions of patients receiving ACT and SP at public health facilities and medicine retailers, though patients were more likely to receive oral artemisinin monotherapy at medicine retailers than public facilities (14% compared to 2%, p \< 0.001). Other anti-malarials, such as chloroquine, amodiaquine and quinine were rarely received by patients. By type of ACT, AL (44%) was most often dispensed and was widely used in the public sector. In medicine retailers, AL was regularly dispensed, though patients also received ASAQ and DHAPQ.

###### 

Anti-malarials received

                                                         Public             Medicine retailer   Total              
  ------------------------------------------------------ ------------------ ------------------- ------------------ ---------
                                                                                                                   
                                                                                                                   
  **Anti-malarials received (all ages)**                 N = 466            N = 1176            N = 1642           
                                                                                                                   
  \% of patients (of all ages) that received:                                                                      
                                                                                                                   
   an anti-malarial                                      54.2 (44.1-63.9)   81.5 (76.2-85.8)    79.3 (74.5-83.4)   \<0.001
                                                                                                                   
   any ACT†                                              17.3 (9.0-30.5)    22.8 (17.2-29.7)    22.4 (17.0-28.8)   0.378
                                                                                                                   
   Artemisinin monotherapy\*                             2.0 (0.8-5.2)      14.4 (11.4-18.0)    13.4 (10.6-16.7)   \<0.001
                                                                                                                   
   Amodiaquine                                           0.1 (0.00-1.0)     2.0 (0.9-4.6)       1.9 (0.8-4.2)      0.002
                                                                                                                   
   Chloroquine                                           2.4 (0.5-10.6)     3.3 (2.0-5.4)       3.2 (2.0-5.2)      0.673
                                                                                                                   
   Quinine                                               0                  0.9 (0.3-2.2)       0.8 (0.3-2.0)      0.501
                                                                                                                   
   SP                                                    33.6 (20.9-49.1)   38.2 (31.8-45.1)    37.9 (31.8-44.3)   0.546
                                                                                                                   
                                                                                                                   
                                                                                                                   
  **Anti-malarials received (children \< 5 yrs only)**   N = 193            N = 107             N = 300            
                                                                                                                   
  \% of children \<5 years that received:                                                                          
                                                                                                                   
   an anti-malarial                                      33.2 (20.0-49.7)   80.2 (63.6-90.4)    67.1 (53.7-78.1)   0.001
                                                                                                                   
   any ACT‡                                              21.3 (9.9-39.9)    31.6 (18.2-49.0)    28.7 (18.0-42.6)   0.329
                                                                                                                   
   Artemisinin monotherapy\*                             2.0 (0.2-14.5)     10.2 (3.4-26.8)     7.9 (2.9-20.2)     0.110
                                                                                                                   
   Amodiaquine                                           0.2 (0.0-3.0)      9.3 (2.3-30.6)      6.7 (1.6-23.8)     0.001
                                                                                                                   
   Chloroquine                                           1.5 (0.7-3.2)      12.6 (4.2-32.1)     9.5 (3.5-23.5)     0.001
                                                                                                                   
   Quinine                                               0                  4.5 (0.6-26.8)      3.23 (0.5-20.2)    0.497
                                                                                                                   
   SP                                                    9.2 (3.7-21.0)     19.9 (8.5-40.0)     16.9 (8.1-32.0)    0.176
                                                                                                                   
                                                                                                                   
                                                                                                                   
  **Type of ACT received**                               N = 105            N = 210             N = 315            
                                                                                                                   
  \% AL                                                  96.5 (92.5-98.4)   40.2 (26.9-55.1)    43.6 (31.0-57.2)   \<0.001
                                                                                                                   
  \% ASAQ                                                3.0 (1.4-6.2)      28.5 (16.1-45.2)    26.9 (15.3-42.8)   \<0.001
                                                                                                                   
  \% DHAPQ                                               0                  24.3 (15.1-36.5)    22.8 (14.3-34.3)   0.074
                                                                                                                   
  \% ASMQ                                                0.5 (0.1-1.9)      4.1 (0.9-16.6)      3.9 (0.9-15.5)     0.019
                                                                                                                   
  \% ASSP                                                0                  2.9 (0.7-11.5)      2.8 (0.7-10.8)     0.648

† At facilities with ACTs in stock 27.0% (20.4-34.7%) of patients at public facilities and 24.2% (17.9-31.9%) of patients at medicine retailers received an ACT

‡ At facilities with ACTs in stock 31.7% (22.0-43.4%) of children under five years at public facilities and 32.5% (18.0-51.3%) of children under five years at medicine retailers received an ACT

\* This was in tablet form at medicine retailers.

Quality of dispensing of ACT
----------------------------

Two-thirds (66%) of all types of ACT dispensed were estimated to be in the correct dose, while 58% of ACT dispensed were in the correct dose and the patient (or their caregiver) accurately reported how the medicine should be taken (Table [5](#T5){ref-type="table"}). Given the challenges in estimating the accuracy of ACT dosage in children, the results are also presented for febrile adults receiving ACT. Overall the results are reasonably similar, with 56% of ACT received in the correct dose and by patients that had accurate knowledge of how to take the medicine. Very few patients receiving an ACT were told of any side effects associated with the medicine.

###### 

Quality of dispensing for patients that received an ACT

                                                                          Public             Medicine retailer   Total              
  ----------------------------------------------------------------------- ------------------ ------------------- ------------------ -------
                                                                                                                                    
                                                                                                                                    
  **All febrile patients that received an ACT\***                         N = 100            N = 176             N = 276            
                                                                                                                                    
  \% accurate dose^†^                                                     75.8 (70.6-80.2)   65.5 (50.1-78.1)    66.2 (51.8-78.0)   0.135
                                                                                                                                    
  \% patient has accurate knowledge of treatment regimen^‡\ i^            68.3 (63.7-72.6)   58.5 (41.6-73.6)    59.2 (43.4-73.3)   0.218
                                                                                                                                    
  \% patients with accurate dose and knowledge of treatment regimen^ii^   66.8 (61.3-71.9)   57.2 (40.3-72.5)    57.8 (41.7-72.4)   0.236
                                                                                                                                    
  \% patients that reported were told of side effects^iii^                1.5 (1.2-1.9)      3.0 (0.6-14.0)      3.0 (0.6-12.9)     0.357
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
  **Febrile adults that received an ACT\***                               N = 21             N = 125             N = 146            
                                                                                                                                    
  \% in accurate dose^†^                                                  72.8 (68.6-76.6)   62.0 (43.5-77.5)    62.2 (44.2-77.4)   0.165
                                                                                                                                    
  \% patient has accurate knowledge of treatment regimen^‡\ iv^           72.8 (68.6-76.6)   55.4 (36.3-73.0)    55.8 (37.1-73.0)   0.051
                                                                                                                                    
  \% patients with accurate dose and knowledge of treatment regimen^iv^   72.8 (68.6-76.6)   55.4 (36.3-73.0)    55.8 (37.1-73.0)   0.051
                                                                                                                                    
  \% patients that reported were told of side effects^v^                  6.2 (5.0-7.7)      4.2 (0.8-18.5)      4.2 (0.9-17.8)     0.570

\* excludes suspensions and syrups and limited to cases for which have data on dosage

† defined as dose that is consistent guidance on dosage by patient age.

‡ defined as patient reports treatment regimen is consistent with guidance on dosage by patient age

i missing 10 observations (2 from public and 8 from medicine retailers)

ii missing 12 observations (4 from public and 8 from medicine retailers)

iii missing 6 observations (2 from public and 4 from medicine retailers)

iv missing 2 observations (from medicine retailers)

v missing 3 observations (from medicine retailers)

Factors influencing treatment received by patients
--------------------------------------------------

The odds of a febrile patient receiving an ACT were significantly associated with whether the patient had a prescription, asked for an ACT, the patient\'s gender, and the education level of the patient (or their caregiver) (Table [6](#T6){ref-type="table"}). Patients were also significantly more likely to receive an ACT at health facilities that were better equipped, and had one or more health workers that knew ACT was recommended for uncomplicated malaria. Patients that chose the health facility because it was convenient or relatively inexpensive were significantly less likely to receive an ACT. Of all the variables considered in the univariable analysis, patients asking for ACT had by far the highest odds ratio of 53.3 (15.9-179.1, p \< 0.001). This variable remained highly significant in the multivariable model with an odds ratio of 55.5 (15.0-205.6, p \< 0.001), though the other significant variables were the patient\'s gender, the education level of the patient (or caregiver), whether the facility had a thermometer available, and whether the facility had health workers that knew ACT was recommended.

###### 

Factors influencing whether a patient received an ACT

  Variable                                                           Univariable Analysis   Multivariable Analysis                                                   
  ------------------------------------------- ----------- ---------- ---------------------- ------------------------ -------------- --------- ------- -------------- ---------
  **Study Site**                              Enugu       211/989    22.7                   1.71                     (0.81-3.61)    0.148                            
                                              Udi         71/531     14.7                   1.0                                                                      
                                                                                                                                                                     
  **Patient characteristics**                                                                                                                                        
                                                                                                                                                                     
  Gender                                      Male        173/795    25.3                   1.63                     (1.00-2.65)    0.051     1.91    (1.02-3.55)    0.045
                                              Female      109/725    17.2                   1.0                                               1.0                    
                                                                                                                                                                     
  Age Group                                   \>15 yrs    157/1023   19.8                   1.0                                     0.336                            
                                              10-15 yrs   16/104     20.7                   1.06                     (0.44-2.53)                                     
                                              5-9 yrs     38/124     37.8                   2.46                     (0.90-6.74)                                     
                                              \<5 yrs     71/269     29.0                   1.65                     (0.88-3.09)                                     
                                                                                                                                                                     
  Quintile                                    Richest     57/230     28.8                   2.35                     (1.12-4.96)    0.201                            
                                              Fourth      48/217     26.2                   2.07                     (0.99-4.35)                                     
                                              Third       48/257     18.7                   1.34                     (0.58-3.12)                                     
                                              Second      61/297     19.8                   1.44                     (0.64-3.25)                                     
                                              Poorest     68/519     14.6                   1.0                                                                      
                                                                                                                                                                     
  Education Level                             No formal   3/61       2.1                    0.09                     (0.02-0.31)    0.001     0.13    (0.03-0.50)    0.045
                                              Primary     45/297     19.9                   1.0                                               1.0                    
                                              Secondary   113/651    19.1                   0.95                     (0.47-1.95)              0.81    (0.35-1.85)    
                                              Tertiary    121/511    25.4                   1.37                     (0.70-2.70)              0.84    (0.41-1.73)    
                                                                                                                                                                     
  First-time go for treatment                 Yes         207/1091   21.5                   0.93                     (0.50-1.73)    0.811                            
                                              No          75/429     22.7                   1.0                                                                      
                                                                                                                                                                     
  Time before treatment                       Same day    30/229     15.5                   1.0                                     0.368                            
                                              1 day       58/302     17.8                   1.17                     (0.49-2.83)                                     
                                              2 days      60/307     23.0                   1.62                     (0.78-3.38)                                     
                                              3-5 days    95/446     28.0                   2.11                     (0.97-4.58)                                     
                                              6+ days     39/236     23.4                   1.66                     (0.64-4.29)                                     
                                                                                                                                                                     
  **Consultation with health worker (HW)**                                                                                                                           
                                                                                                                                                                     
  HW told of symptoms                         Yes         170/1030   18.0                   0.65                     (0.34-1.22)    0.162                            
                                              No          112/490    25.4                   1.0                                                                      
                                                                                                                                                                     
  HW is told of patient\'s fever              Yes         165/961    19.2                   0.76                     (0.41-1.43)    0.373                            
                                              No          117/559    23.8                   1.0                                                                      
                                                                                                                                                                     
  HW asks follow up Qs                        Yes         139/700    23.6                   1.33                     (0.68-2.61)    0.376                            
                                              No          143/819    18.5                   1.0                                                                      
                                                                                                                                                                     
  Patient is examined                         Yes         83/370     19.5                   0.88                     (0.42-1.87)    0.724                            
                                              No          199/1150   22.0                   1.0                                                                      
                                                                                                                                                                     
  Takes patient temperature                   Yes         53/251     19.1                   0.90                     (0.44-1.85)    0.755                            
                                              No          229/1269   21.9                   1.0                                                                      
                                                                                                                                                                     
  Patient has a prescription                  Yes         99/327     42.1                   3.51                     (1.77-6.95)    0.001                            
                                              No          183/1193   17.1                   1.0                                                                      
                                                                                                                                                                     
  Asked for ACT                               Yes         114/138    86.2                   53.28                    (15.9-179.1)   \<0.001   55.47   (15.0-205.6)   \<0.001
                                              No          168/1382   10.6                   1.0                                               1.0                    
                                                                                                                                                                     
  **Health facility characteristics**                                                                                                                                
                                                                                                                                                                     
  Type of facility                            Public      94/430     16.6                   0.70                     (0.29-1.67)    0.385                            
                                              Retailer    188/1090   22.2                   1.0                                                                      
                                                                                                                                                                     
  Weighing scale available                    Yes         216/892    27.2                   2.13                     (1.05-4.32)    0.037                            
                                              No          66/628     14.6                   1.0                                                                      
                                                                                                                                                                     
  Thermometer available                       Yes         198/872    27.5                   1.94                     (1.01-3.71)    0.046     1.99    (0.94-4.18)    0.068
                                              No          84/648     16.2                   1.0                                               1.0                    
                                                                                                                                                                     
  Offer malaria microscopy                    Yes         17/70      24.0                   1.12                     (0.77-1.63)    0.519                            
                                              No          265/1430   21.7                   1.0                                                                      
                                                                                                                                                                     
  **Facility has one or more HWs that\...**                                                                                                                          
                                                                                                                                                                     
  \... have attended malaria training         Yes         137/660    22.0                   1.03                     (0.52-2.02)    0.927                            
                                              No          145/860    21.6                   1.0                                                                      
                                                                                                                                                                     
  \... have access to guidelines              Yes         66/236     19.2                   0.83                     (0.51-1.34)    0.413                            
                                              No          216/1284   22.0                   1.0                                                                      
                                                                                                                                                                     
  \... know ACT is recommended                Yes         251/1136   24.8                   2.40                     (1.03-5.57)    0.043     2.47    (0.91-6.73)    0.073
                                              No          31/384     11.5                   1.0                                                                      

Discussion
==========

There is great need to improve the quality of care for uncomplicated malaria in south-eastern Nigeria. Parasitological diagnosis was available in only 3% of facilities and while the national malaria treatment guidelines recommend presumptive treatment of a fever with ACT when malaria tests are not available, less than a quarter (22%) of febrile patients attending facilities received the recommended treatment. Moreover, the estimates show that only 58% of patients that received ACT were given the correct dose and knew how the medicine should be taken. Inadequate dosing and poor compliance to treatment regimens will reduce the efficacy of the treatment taken and may contribute to the development of drug resistance \[[@B25]\].

After four years with ACT as the recommended first-line antimalarial, these results at public health facilities are extremely concerning. In Kenya and Zambia poor quality treatment practices were observed at public and mission facilities soon after ACT was introduced as first-line, though subsequent studies up to five years later show improvements in the proportion of patients that are prescribed and receive ACT \[[@B3],[@B7],[@B26]\]. As found elsewhere, the proportion of patients that were prescribed or received an ACT seems low given the availability of ACT at health facilities and the proportion of health workers that knew ACT was recommended \[[@B3],[@B7],[@B27],[@B28]\]. It was also interesting to note that only half of patients at public facilities that were prescribed an ACT also received one, though it is not clear why this occurred: 34% of patients at public facilities were prescribed an ACT, while 17% received an ACT. The discrepancy is only partially explained by the availability of ACT and is unlikely to reflect the cost of treatment, as ACT is provided to patients in public facilities without charge.

There were some problems with the availability of ACT: 70% of public facilities and 83% of pharmacies and PMDs had at least one ACT in stock at the time of the survey. While the availability of ACT in the public sector was not as high as has been reported in Angola, Kenya, or Uganda \[[@B7],[@B9],[@B28]-[@B30]\], the availability of ACT in the study sites was much higher than the Nigerian national average from 2008, when it was found that 38% of public health facilities had ACT in stock. The availability of ACT at private sector outlets was found to be higher than the Nigerian national average from 2008, which reported 78% of pharmacies and 19% of PMDs had ACT in stock \[[@B9]\]. It is concerning to find that artemisinin monotherapy is widely available in medicine retailers and that many patients request this medicine. The use of oral artemisinin monotherapy in 13.4% of patients is also a major concern, since its use without a combination therapy can lead to the development of drug resistance \[[@B5],[@B6]\].

Differences observed between the characteristics of patients by type of health facility are broadly consistent with evidence from household surveys conducted in Nigeria on malaria treatment seeking. For example, rural-urban differences, the education of caregivers, and socioeconomic status have been found to be important determinants of where treatment is sought \[[@B14],[@B15],[@B31]-[@B33]\]. Other studies have also shown that urban residents were more likely to obtain ACT \[[@B15]\] and individuals of higher levels of education and socioeconomic status were more likely to have correct knowledge of malaria treatment \[[@B31]\].

Differences between the facility types in the resources available and the patient\'s consultation were much as expected, with patients attending public health facilities more likely to discuss symptoms and be examined. Similarly, as pharmacies and PMDs are retail outlets it is not surprising that many lacked weighing scales and thermometers and that patients often asked for specific medicines. Moreover, it was expected that health workers in public facilities would have better access to the malaria treatment guidelines and be more likely to know that ACT is recommended for uncomplicated malaria.

The odds of a febrile patient receiving an ACT were positively associated with the health workers knowledge of the treatment guidelines, though there is no evidence of an association between access to treatment guidelines and attendance at malaria training. It should be noted that these variables were defined at the facility-level because in many cases it was not possible to link patients to the health worker that prescribed or recommended treatment, either because the health worker was absent at the time of the survey or because several health workers attended to the patient.

The treatment received by patients from medicine retailers was often driven by consumer requests for a specific medicine, and the odds of a febrile patient receiving an ACT were extremely high if the patient or their caregiver had asked for one. Previous studies from Nigeria have also highlighted the importance of patient demand. For example, Onwujekwe *et al*reports that 40% of providers across a range of primary health facilities said requests by patients influenced the type of drug provided \[[@B4]\]. Qualitative research with patent medicine dealers undertaken by Okeke *et al*also highlighted that patients often ask for specific medicines and the doses of anti-malarial drugs can be determined by patient\'s ability to pay \[[@B18]\]. Patients\' requests for specific medicine at medicine retailers were likely to include cases for which treatment had been prescribed elsewhere, though as only 15% of patients had a prescription other factors are likely to be relevant and there would be merit in further examining the role of patient demand in influencing the choice of treatment for uncomplicated malaria in private sector facilities.

Conclusions
===========

ACT became the recommended treatment for uncomplicated malaria in 2005, though they remain underused, and less than a quarter of febrile patients attending health facilities in this study received ACT. Although there is increasing emphasis on the parasitological rather than symptomatic diagnosis of malaria, the study suggests that there is a need for interventions that also focus on choice of treatment to ensure that patients with malaria receive the recommended anti-malarial, irrespective of the diagnostic method. Improving the provision of health services should also address the quality of dispensing, and ensure that health workers can accurately determine the correct dose across a range of different brands and types of ACT. Concurrently attention needs to be given to the high availability and use of artemisinin monotherapy, as well as the continued use of less effective treatments, particularly SP. Consideration should also be given to the role of patient demand in influencing the treatment received, especially in medicine retailers, since this was found to be a major determinant of whether patients received an ACT. Thus, in developing interventions to improve malaria case management the results demonstrate the importance of addressing both demand and supply-side influences on malaria treatment.
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